DDInter1073 DDInter1376
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Linezolid {u} (Compound) resembles {v} (Compound) Rivaroxaban
Linezolid {u} (Compound) binds {v} (Gene) MAOB
Linezolid {u} (Compound) upregulates {v} (Gene) ZFP36
Linezolid {u} (Compound) is included by {v} (Pharmacologic Class) Oxazolidinones
Linezolid {u} (Compound) downregulates {v} (Gene) IER3
Linezolid {u} (Compound) causes {v} (Side Effect) Thrombophlebitis
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Linezolid {u} may lead to a major life threatening interaction when taken with {v} Epinephrine
Linezolid {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Linezolid (Compound) resembles Rivaroxaban (Compound)
Linezolid (Compound) binds MAOB (Gene)
Linezolid (Compound) upregulates ZFP36 (Gene)
Linezolid (Compound) is included by Oxazolidinones (Pharmacologic Class)
Linezolid (Compound) downregulates IER3 (Gene)
Linezolid (Compound) causes Thrombophlebitis (Side Effect)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Dapsone
Linezolid may lead to a major life threatening interaction when taken with Epinephrine
Linezolid may lead to a major life threatening interaction when taken with Cladribine